Tumor mutational burden (TMB) is an increasingly important clinical biomarker for emerging immuno-oncology (IO) therapeutics.
Join us for a clinical laboratoryâ€™s perspective on validating targeted NGS panels to support IO clinical trial projects using the first of its kind, purpose-built TMB reference materials. We will discuss the challenges of accurately measuring TMB in blood and tissue, and the development and application of reference materials to ensure the quality, standardization, and harmonization of TMB measurement by NGS.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences